Medindia

X

Hyderabad-Based Company Secures Five Country Patent for Its Neuro-Degenerative Drug

by Reshma Anand on  October 13, 2015 at 5:49 PM Corporate News   - G J E 4
Suven Life Sciences has been granted patent for a drug used in the treatment of neuro-degenerative diseases by Australia, China, Europe, South Korea and the US. The patents are valid until 2031, 2030, 2031, 2030 and 2031, respectively.
Hyderabad-Based Company Secures Five Country Patent for Its Neuro-Degenerative Drug
Hyderabad-Based Company Secures Five Country Patent for Its Neuro-Degenerative Drug
Advertisement

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."

Advertisement
The company has "secured patents in Australia, China, Europe, South Korea and USA to their new chemical entities for CNS therapy through mechanism of action H3 Inverse against."

With these new patents, Suven has a total of 22 granted patents from Australia, 19 from China, 17 from Europe, 17 from South Korea and 23 from the US.

"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," Suven said.

Source: PTI
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like